{"nctId":"NCT00367640","briefTitle":"Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis","startDateStruct":{"date":"2004-11"},"conditions":["Allergy"],"count":628,"armGroups":[{"label":"100 IR","type":"EXPERIMENTAL","interventionNames":["Drug: 100 IR grass pollen allergen extract tablet"]},{"label":"300 IR","type":"EXPERIMENTAL","interventionNames":["Drug: 300 IR grass pollen allergen extract tablet"]},{"label":"500 IR","type":"EXPERIMENTAL","interventionNames":["Drug: 500 IR grass pollen allergen extract tablet"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo tablet"]}],"interventions":[{"name":"100 IR grass pollen allergen extract tablet","otherNames":["Sublingual immunotherapy tablet"]},{"name":"300 IR grass pollen allergen extract tablet","otherNames":["Sublingual immunotherapy tablet"]},{"name":"500 IR grass pollen allergen extract tablet","otherNames":["Sublingual immunotherapy tablet"]},{"name":"Placebo tablet","otherNames":["Sublingual placebo tablet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written consent\n* Grass-pollen related allergic rhinoconjunctivitis for at least the last 2 pollen seasons.\n* Sensitised to grass pollen (positive SPT and RAST level of at least class 2).\n* Total symptom score of the RRTSS during the previous pollen season greater than or equal to 12.\n* Safety laboratory resuts within the references ranges\n\nExclusion Criteria:\n\n* Pregnancy, breast-feeding/lactation\n* Had received desensitisation treatment for grass pollen\n* Treatment by immunotherapy with another allergen within the previous 5 years\n* Usual contraindications of immunotherapy such as serious immunopathologic conditions or malignancies\n* Treated with beta-blockers or under continuous corticotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Rhinoconjunctivitis Total Symptom Score","description":"Average Rhinoconjunctivitis Total Symptom Score during the pollen period while participant on treatment.\n\nParticipants assessed daily, during the pollen period, 6 rhinoconjunctivitis symptoms (sneezing, rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus and watery eyes) each symptom is scored as follows: 0: no symptoms, 1: mild symptoms, 2: moderate symptoms, 3: severe symptoms. The sum of the 6 symptoms is the Rhinoconjunctivitis Total Symptom Score (RTSS) (range 0-18). The lower the score, the better the outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.72","spread":"3.141"},{"groupId":"OG001","value":"3.58","spread":"2.976"},{"groupId":"OG002","value":"3.74","spread":"3.142"},{"groupId":"OG003","value":"4.93","spread":"3.229"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":160},"commonTop":["ORAL PRURITUS","HEADACHE","THROAT IRRITATION","NASOPHARYNGITIS","OEDEMA MOUTH"]}}}